Catherine Deloche
Overview
Explore the profile of Catherine Deloche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aptel F, Colin C, Kaderli S, Deloche C, Bron A, Stewart M, et al.
Br J Ophthalmol
. 2017 Aug;
101(11):1-10.
PMID: 28774934
Prevention and management of postoperative ocular inflammation with corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) have been evaluated in several randomised controlled trials (RCTs). However, neither consensus regarding the efficacies of...
2.
Chiquet C, Aptel F, Creuzot-Garcher C, Berrod J, Kodjikian L, Massin P, et al.
Am J Ophthalmol
. 2016 Nov;
174:76-84.
PMID: 27810317
Purpose: To evaluate the efficacy and safety of XG-102 (brimapitide) compared to dexamethasone eye drops in the treatment of postoperative ocular inflammation. Design: Multicenter, randomized, parallel group, double-masked, noninferiority clinical...
3.
Deloche C, Lopez-Lazaro L, Mouz S, Perino J, Abadie C, Combette J
Pharmacol Res Perspect
. 2014 Dec;
2(1):e00020.
PMID: 25505576
The aim of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of the JNK inhibitor XG-102 in a randomized, double blind, placebo controlled, sequential ascending dose parallel...
4.
Beydoun T, Deloche C, Perino J, Kirwan B, Combette J, Behar-Cohen F
J Ocul Pharmacol Ther
. 2014 Oct;
31(2):93-9.
PMID: 25347151
Purpose: We aimed to investigate the safety, tolerability, and systemic diffusion of a single escalating dose of XG-102 (a 31-D-amino-acid peptide inhibiting JNK pathway activation), administered subconjunctivally in the treatment...
5.
El Zaoui I, Touchard E, Berdugo M, Abadie C, Kowalczuk L, Deloche C, et al.
J Ocul Pharmacol Ther
. 2014 Oct;
31(1):17-24.
PMID: 25313830
Purpose: XG-102, a TAT-coupled dextrogyre peptide inhibiting the c-Jun N-terminal kinase, was shown efficient in the treatment of experimental uveitis. Preclinical studies are now performed to determine optimal XG-102 dose...
6.
Berdugo M, Larsen I, Abadie C, Deloche C, Kowalczuk L, Touchard E, et al.
Antimicrob Agents Chemother
. 2011 Dec;
56(3):1390-402.
PMID: 22203590
Herpes simplex ocular infection is a major cause of corneal blindness. Local antiviral treatments exist but are associated with corneal toxicity, and resistance has become an issue. We evaluated the...
7.
Touchard E, Omri S, Naud M, Berdugo M, Deloche C, Abadie C, et al.
Invest Ophthalmol Vis Sci
. 2010 Apr;
51(9):4683-93.
PMID: 20393119
Purpose: To evaluate the effect of XG-102 (formerly D-JNKI1), a TAT-coupled dextrogyre peptide that selectively inhibits the c-Jun N-terminal kinase, in the treatment of endotoxin-induced uveitis (EIU). Methods: EIU was...